STAR0602

Phase 2Small molecule

MMarengo Therapeutics, Inc.

STAR0602 is one of 66 small molecule programs targeting Solid Tumor. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Solid TumorRecruiting

Advanced Solid TumorsRecruiting

Solid TumorPreclinical

Recruiting

Advanced Solid TumorsPhase 2

Recruiting

Competition

Competitive Landscape

348 competitors in Solid Tumor

#DrugCompanyPhaseTrials

Yervoy

Bristol-Myers Squibb

Preclinical

3 2

Fludara

Sanofi

Preclinical

2 3

Zejula

GGlaxo Dba Glaxosmithkline

Preclinical

2 4

STAR0602

MMarengo Therapeutics, Inc.

Phase 2

1 5

Navmi

SSummit Therapeutics

Preclinical

1 6

Proleukin

IIovance Biotherapeutics, Inc.

Preclinical

1 7

Soc

Pfizer

Preclinical

1 8

Ifinatamab Deruxtecan

Daiichi Sankyo

Preclinical

1 9

Tulmimetostat

Novartis

Preclinical

1 10

Carboplatin AUC-5

Merck & Co.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

PreclinicalRecruiting

Solid Tumor

NCT05592626

Q1 2028

Phase 1/2Recruiting

Advanced Solid Tumors

NCT06827613

Q2 2030

PreclinicalNot yet recruiting

NSCLC

NCT07902921

Clinical

Trials by Indication[1]

Advanced Solid Tumors1 trial

A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors

Recruiting·MMarengo Therapeutics, Inc.·Phase 1/2·NCT06827613·50 enrolled

NSCLC1 trial

A Phase Ib/II Study of STAR0602 With Nivolumab in Non-Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma

Not yet recruiting·NNational Cancer Institute (NCI)·Preclinical·NCT07902921·67 enrolled

Solid Tumor1 trial

A Phase 1/2, First-in-Human, Open-Label, Dose Escalation and Expansion Study of STAR0602, a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule, in Subjects With Unresectable, Locally Advanced, or Metastatic Solid Tumors That Are Antigen-rich (START-001)

Recruiting·MMarengo Therapeutics, Inc.·Preclinical·NCT05592626·366 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for STAR0602. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — STAR0602 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for STAR0602. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Marengo Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: MMarengo Therapeutics, Inc.

STAR0602

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q1 2028

Q2 2030

Trials by Indication[1]

Advanced Solid Tumors1 trial

NSCLC1 trial

Solid Tumor1 trial

References

Drug Info

Quick Facts

Related News